Literature DB >> 22311298

Effective down-regulation of breast cancer resistance protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers.

Hamidreza Montazeri Aliabadi1, Breanne Landry, Parvin Mahdipoor, Charlie Y M Hsu, Hasan Uludağ.   

Abstract

Breast Cancer Resistance Protein (BCRP, ABCG2) is an efflux protein whose aberrant activity has been linked to multidrug resistance in cancer. Although siRNA delivery to down-regulate BCRP expression is promising to sensitize tumor cells against drugs, therapeutic use of siRNA requires effective carriers that can deliver siRNA intracellularly with minimal toxicity on target cells. This study explored the feasibility of special class of cationic polymers, namely lipid-substituted low molecular weight (2kDa) polyethyleneimine (PEI), as a carrier for siRNA-mediated BCRP down-regulation. Structure-function studies methodically evaluated the effect of a range of lipophilic substitutions for siRNA delivery and BCRP down-regulation. Our results showed a significant increase in siRNA delivery as a function of lipid substitution for a range of lipids ranging from C8 to C18. The BCRP silencing was correlated to siRNA delivery efficiency of the polymers, and effectively lasted for ∼5days after a single treatment of siRNA. BCRP down-regulation sensitized the drug-resistant cells to cytotoxic effect of mitoxantrone by a ∼14-fold decrease in the IC(50) value, whose effect was evident even after 14days. This study demonstrated the possibility of functional siRNA delivery by lipid-modified low molecular weight PEI and highlighted the importance of the extent and nature of lipid substitution in effective siRNA delivery.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22311298     DOI: 10.1016/j.ejpb.2012.01.011

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  8 in total

1.  Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy.

Authors:  Hamidreza Montazeri Aliabadi; Parvin Mahdipoor; Cezary Kucharsky; Nicole Chan; Hasan Uludağ
Journal:  Pharm Res       Date:  2015-07-01       Impact factor: 4.200

2.  Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines.

Authors:  Samarwadee Plianwong; Bindu Thapa; Remant Bahadur Kc; Cezary Kucharski; Theerasak Rojanarata; Hasan Uludağ
Journal:  Pharm Res       Date:  2020-02-03       Impact factor: 4.200

Review 3.  Non-viral nanocarriers for siRNA delivery in breast cancer.

Authors:  Jing Zhang; Xiang Li; Leaf Huang
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

4.  Therapeutic nanosystems for oncology nanomedicine.

Authors:  A S Gonçalves; A S Macedo; E B Souto
Journal:  Clin Transl Oncol       Date:  2012-07-27       Impact factor: 3.405

5.  PI3K/Akt inhibition and down-regulation of BCRP re-sensitize MCF7 breast cancer cell line to mitoxantrone chemotherapy.

Authors:  Tahereh Komeili-Movahhed; Shamileh Fouladdel; Elmira Barzegar; Shekoufeh Atashpour; Mohammad Hossein Ghahremani; Seyed Nasser Ostad; Zahra Madjd; Ebrahim Azizi
Journal:  Iran J Basic Med Sci       Date:  2015-05       Impact factor: 2.699

6.  Tumor-targeted delivery of siRNA using fatty acyl-CGKRK peptide conjugates.

Authors:  Meenakshi Sharma; Naglaa Salem El-Sayed; Hung Do; Keykavous Parang; Rakesh Kumar Tiwari; Hamidreza Montazeri Aliabadi
Journal:  Sci Rep       Date:  2017-07-21       Impact factor: 4.379

7.  Radiation-enhanced delivery of plasmid DNA to tumors utilizing a novel PEI polyplex.

Authors:  Oliver K Appelbe; Bieong-Kil Kim; Nick Rymut; Jianping Wang; Stephen J Kron; Yoon Yeo
Journal:  Cancer Gene Ther       Date:  2017-12-19       Impact factor: 5.987

Review 8.  Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1.

Authors:  Terra Arnason; Troy Harkness
Journal:  Cancers (Basel)       Date:  2015-10-16       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.